公开(公告)号：US12043610B2

公开(公告)日：2024-07-23

申请号：US17730463

申请日：2022-04-27

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC分类号： C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

CPC分类号： C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

摘要： Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US20240239752A1

公开(公告)日：2024-07-18

申请号：US18286615

申请日：2022-04-14

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Zhao Dang ,  Krishnan Raman

IPC分类号： C07D231/56 ,  A61K31/343 ,  A61K31/352 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  C07D217/22 ,  C07D307/81 ,  C07D311/96 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

CPC分类号： C07D231/56 ,  A61K31/343 ,  A61K31/352 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  C07D217/22 ,  C07D307/81 ,  C07D311/96 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

摘要： Disclosed are compounds of formulae (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity, such as Netherton Syndrome.

公开(公告)号：US11708332B2

公开(公告)日：2023-07-25

申请号：US17526377

申请日：2021-11-15

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Minwan Wu ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Weihe Zhang

IPC分类号： C07D231/14 ,  C07D403/12 ,  C07D401/14 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12

CPC分类号： C07D231/14 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12

摘要： Disclosed are compounds of formula I






as described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

公开(公告)号：US20220332723A1

公开(公告)日：2022-10-20

申请号：US16622816

申请日：2018-06-14

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. Kotian ,  Yarlagadda S. Babu ,  V. Satish Kumar ,  Weihe Zhang ,  Peng-Cheng Lu ,  Krishnan Raman

IPC分类号： C07D491/048 ,  C07D487/04 ,  C07D495/04 ,  C07D403/12 ,  C07D403/14 ,  C07D471/04 ,  C07D513/04 ,  C07D401/14 ,  C07D405/14 ,  C07D405/12

摘要： Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

公开(公告)号：US10329260B2

公开(公告)日：2019-06-25

申请号：US15977129

申请日：2018-05-11

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Minwan Wu ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Weihe Zhang

IPC分类号： C07D231/14 ,  C07D417/12 ,  C07D413/12 ,  C07D413/04 ,  C07D405/12 ,  C07D403/12 ,  C07D401/12 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04

摘要： Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

公开(公告)号：US11661426B2

公开(公告)日：2023-05-30

申请号：US16622816

申请日：2018-06-14

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. Kotian ,  Yarlagadda S. Babu ,  V. Satish Kumar ,  Weihe Zhang ,  Peng-Cheng Lu ,  Krishnan Raman

IPC分类号： C07D401/14 ,  C07D491/048 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

CPC分类号： C07D491/048 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

摘要： Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.

公开(公告)号：US20230100082A1

公开(公告)日：2023-03-30

申请号：US17526377

申请日：2021-11-15

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. KOTIAN ,  Yarlagadda S. Babu ,  Minwan Wu ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Weihe Zhang

IPC分类号： C07D231/14 ,  C07D403/12 ,  C07D401/14 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12

摘要： Disclosed are compounds of formula I as described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

公开(公告)号：US20230094305A1

公开(公告)日：2023-03-30

申请号：US17543929

申请日：2021-12-07

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Minwan Wu ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Weihe Zhang

IPC分类号： C07D231/14 ,  C07D403/12 ,  C07D401/14 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12

摘要： Disclosed are compounds of formula I: as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

公开(公告)号：US20230072867A1

公开(公告)日：2023-03-09

申请号：US17730463

申请日：2022-04-27

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC分类号： C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

摘要： Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US20220356166A1

公开(公告)日：2022-11-10

申请号：US17168574

申请日：2021-02-05

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC分类号： C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

摘要： Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.